JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

Home・Aandelen Lijst・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

4.84 4.09

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.59

Max

4.87

Belangrijke statistieken
By Trading Economics
Inkomsten	21M 61M
Verkoop	-74M 48M
K/W Sectorgemiddelde	28.688 67.147
Winstmarge	128.703
Werknemers	100
EBITDA	-68M 8.8M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+117.86% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	146M 756M
Vorige openingsprijs	0.75
Vorige sluitingsprijs	4.84

Nieuwssentiment

By Acuity

50%

180 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

N/A / 0.9337 Steun & Weerstand

Ironwood Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 mei 2026, 23:43 UTC

Belangrijke Nieuwsgebeurtenissen

New Zealand's Unemployment Rate Falls in 1Q

5 mei 2026, 23:20 UTC

Populaire aandelen

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mei 2026, 21:48 UTC

Winsten

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mei 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mei 2026, 00:00 UTC

Marktinformatie

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mei 2026, 23:39 UTC

Marktinformatie

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mei 2026, 22:26 UTC

Marktinformatie

AMD Data-Center Business Continues to Surge -- Market Talk

5 mei 2026, 22:20 UTC

Marktinformatie

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mei 2026, 22:08 UTC

Winsten

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mei 2026, 22:07 UTC

Winsten

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:48 UTC

Winsten

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mei 2026, 21:48 UTC

Winsten

Pan American Silver 1Q Rev $1.2B >PAAS

5 mei 2026, 21:42 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:38 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:30 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:29 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:26 UTC

Winsten

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mei 2026, 21:25 UTC

Winsten

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mei 2026, 21:25 UTC

Winsten

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mei 2026, 21:24 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:18 UTC

Winsten

Mistras Backs 2026 Rev $730M-$750M >MG

5 mei 2026, 21:17 UTC

Winsten

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mei 2026, 21:15 UTC

Winsten

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mei 2026, 21:12 UTC

Winsten

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mei 2026, 21:11 UTC

Winsten

SSR Mining 1Q Rev $581.8M >SSRM

5 mei 2026, 21:10 UTC

Winsten

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mei 2026, 21:10 UTC

Winsten

SSR Mining 1Q EPS $1.16 >SSRM

5 mei 2026, 21:08 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:01 UTC

Winsten

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mei 2026, 21:01 UTC

Populaire aandelen

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Peer Vergelijking

Prijswijziging

Ironwood Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

117.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 10 USD 117.86%

Hoogste 10 USD

Laagste 10 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ironwood Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Ironwood Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

N/A / 0.9337Steun & Weerstand

Recent bearish events outweigh bullish events.

There are no events.

All events are bearish.

Sentiment

By Acuity

180 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.